

LICENCE WITHDRAWN

Please refer to the European Medicines Agency website for further information

Final Appraisal Recommendation

Advice No: 1013 – May 2013

**Ingenol mebutate (Picato[®]▼)
150 micrograms/g gel and 500 micrograms/g gel**

Submission by LEO Laboratories Ltd

Recommendation of AWMSG

Ingenol mebutate (Picato[®]▼) is recommended as an option for use within NHS Wales for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.

In reaching the above recommendation, AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1392), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

| | |
|------------------------------------------------|----------------------|
| Marketing authorisation holder on first issue: | LEO Laboratories Ltd |
| Date of first issue | May 2013 |
| Last reviewed | June 2020 |

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1013:
Ingenol mebutate (Picato[®]▼) 150 micrograms/g gel and 500 micrograms/g gel. May 2013.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.